Prevalence of human leukocyte antigen HLA-B*57:01 in HIV-infected subjects in the Czech Republic.

The HLA-B*57:01 allele is associated with a hypersensitivity reaction to abacavir, and its prevalence varies in different populations. The aim of the study was to investigate HLA-B*57:01 prevalence in the Czech HIV-infected population. HLA-B*57:01 prevalence in our cohort was 5.33%, which is similar to the situation in other Central European countries.

[1]  Yao Ju,et al.  HLA-B~*5701 screening for hypersensitivity to abacavir , 2011 .

[2]  A. Urbańska,et al.  Introduction of pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 variant in Polish HIV‐infected patients , 2010, HIV medicine.

[3]  C. Orkin,et al.  Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)‐B*5701 in HIV‐1‐infected UK subjects , 2010, HIV medicine.

[4]  H. Faruki,et al.  HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, Personalized medicine.

[5]  S. Mallal,et al.  High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Foisy,et al.  Abacavir Hypersensitivity Reaction: an Update , 2008, The Annals of pharmacotherapy.

[7]  Hsin-Yun Sun,et al.  Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. , 2007, The Journal of antimicrobial chemotherapy.

[8]  I. James,et al.  Immune responses to abacavir in antigen-presenting cells from hypersensitive patients , 2007, AIDS.

[9]  S. Mallal,et al.  Clinical and immunogenetic correlates of abacavir hypersensitivity , 2005, AIDS.

[10]  E. Ivašková,et al.  HLA-A, -B, -Cw, -DPB1, -DQA1, -DQB1 and -DRB1 allele frequencies in a population from the Czech Republic , 2004 .

[11]  M. Pirmohamed,et al.  Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. , 2004, Pharmacogenetics.

[12]  Clive E. Bowman,et al.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir , 2002, The Lancet.

[13]  O. Naderer,et al.  Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. , 2001, Clinical therapeutics.

[14]  C. Moore,et al.  HLA-DQ 3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2022 .